Experimental Hematology
Volume 38, Issue 6 , Pages 462-471 , June 2010

Circulating CD33 and its clinical value in acute leukemia

  • Adam Abdool

      Affiliations

    • Hematology and Oncology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • ,
  • Chen-Hsiung Yeh

      Affiliations

    • Hematology and Oncology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • ,
  • Hagop Kantarjian

      Affiliations

    • Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
    • ,
  • Susan O'Brien

      Affiliations

    • Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
    • ,
  • Jean Marie Bruey

      Affiliations

    • Hematology and Oncology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • ,
  • Francis Giles

      Affiliations

    • University of Texas, Health Science Center, San Antonio, Tex., USA
    • ,
  • Maher Albitar

      Affiliations

    • Hematology and Oncology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • Corresponding Author InformationOffprint requests to: Maher Albitar, M.D., Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92675

Received 26 October 2009 ,Revised 23 February 2010 ,Accepted 25 March 2010.

References 

  1. Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell–cell interactions and signalling. Curr Opin Struct Biol. 2002;12:609–615
  2. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19:176–182
  3. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem. 1999;274:11505–11512
  4. Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with the Syk and/or ZAP-70 expression. Exp Hematol. 2003;31:363–371
  5. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105:1295–1302
  6. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048–1053
  7. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521–534
  8. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72:314–321
  9. Sievers EL, Larson RA, Stadtmauer EA, et al. Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254
  10. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47–58
  11. Bernstein ID. CD33 as target for selective ablation of acute myeloid leukemia. Clin Lymphoma. 2002;2(Suppl 1):S9–S11
  12. Sperr WR, Florian S, Hauswirth AW, Valent P. CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma. 2005;46:1115–1120
  13. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436–1443
  14. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254
  15. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627–1636
  16. Van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18:983–988
  17. Zwaan CM, Reinhardt D, Jurgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 2003;17:468–470
  18. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol. 2003;71:1–8
  19. Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118:560–566
  20. Manshouri T, Do K, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  21. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;41:77–78

PII: S0301-472X(10)00131-1

doi: 10.1016/j.exphem.2010.03.016

Experimental Hematology
Volume 38, Issue 6 , Pages 462-471 , June 2010

Article Tools

* Image Usage & Resolution